CITORREDUCCION EN POBLACIÓN NO SELECCIONADA
PRIME study post-hoc analysis
ETS and response (WT
RAS
)
•
Douillard JY, et al. Eur J Cancer 2015;51:1231−42.
Updated analysis
Panitumumab
+ FOLFOX4
FOLFOX4
Objective response,* n (%)
150 (60)
115 (47)
% difference (95% CI)
P-value
†
13.7 (5.0–22.4)
0.003
ETS ≥ 30% at Week 8,
‡
n (%)
130 (59)
83 (38)
% difference (95% CI)
P-value
†
21.8 (12.7–30.9)
< 0.001
ETS ≥ 20% at Week 8,
‡
n (%)
158 (72)
125 (57)
% difference (95% CI)
P-value
†
15.6 (6.8–24.4)
< 0.001
Median TTR,
*
months
3.4
NE
HR
§
(95% CI)
P-value
#
0.65 (0.51–0.83)
0.0006
Median DpR,
¥
% (Q1, Q3)
54 (31, 72)
46 (23, 66)
P- value
P = 0.0149
